Results 71 to 80 of about 5,687 (195)

Use of modeling and simulation to predict the influence of triazole antifungal agents on the pharmacokinetics of zanubrutinib and acalabrutinib

Frontiers in Pharmacology, 2022
Background: Bruton’s tyrosine kinase (BTK) inhibitors are commonly used in the targeted therapy of B-cell malignancies. It is reported that myelosuppression and fungal infections might occur during antitumor therapy of BTK inhibitors, therefore a ...
Lu Chen, Chao Li, Hao Bai, Lixian Li, Wanyi Chen, Wanyi Chen   +5 more
doaj   +1 more source

Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease [PDF]

, 2020
The proteasome is the central component of the main cellular protein degradation pathway. During the past four decades, the critical function of the proteasome in numerous physiological processes has been revealed, and proteasome activity has been linked
Li, Jing, Sherman, David J.
core  

Population Pharmacokinetic Modeling and Exposure‐Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Nemtabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor under clinical investigation in patients with hematologic malignancies, including chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Nemtabrutinib plasma concentration data from 578 patients enrolled in phase 1 and 2 clinical studies, treated with doses from 5 to ...
Chiara C. Kemal, Thijs J. Zweers, Elke H. J. Krekels, Manash S. Chatterjee   +3 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Low dose Btk inhibitors selectively block platelet activation by CLEC-2 [PDF]

, 2020
Inhibitors of the tyrosine kinase Btk have been proposed as novel antiplatelet agents. In this study we show that low concentrations of the Btk inhibitor ibrutinib block CLEC-2-mediated activation and tyrosine phosphorylation including Syk and PLCγ2 in ...
Brill, Alexander, Campos, Joana, Clifford, Hayley, Eble, Johannes A, Garcia-Quintanilla, Lourdes, Hinds, Joshua, Hughes, Craig E, Huissoon, Aarnoud P, Kavanagh, Deidre M, Khan, Abdullah O, Nicolson, Phillip LR, Nock, Sophie H, Pike, Jeremy A, Pollitt, Alice Y, Poulter, Natalie S, Pratt, Guy, Smith, Christopher W, Watson, Callum N, Watson, Stephanie, Watson, Steve P   +19 more
core   +5 more sources

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 4, Page 832-863, April 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source

Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. [PDF]

, 2019
Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of ...
Chan, Alexandre, Klibanov, Olga, Olin, Jacqueline L, Spooner, Linda M   +3 more
core   +1 more source

Life‐Threatening Acute Tumor Lysis Syndrome With Multiorgan Failure Following First Cycle of Bendamustine–Rituximab in Chronic Lymphocytic Leukemia: A Case Report and Brief Review

Clinical Case Reports, Volume 14, Issue 4, April 2026.
Graphical timeline of the patient’s clinical course. The timeline illustrates key events in a patient with CLL who developed acute tumor lysis syndrome after the first cycle of bendamustine–rituximab, including TLS onset, multiorgan failure, hemodialysis, and full recovery. ABSTRACT Chronic lymphocytic leukemia is not uniformly low risk for tumor lysis
Malegna Temesgen Garuma, Kebede H. Begna, Tesfaye Belete Amare, Mengisteab Kassahun Desta, Derebe Shashigo Leilago, Humud Mohammed Ahmed   +5 more
wiley   +1 more source

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases

Journal of Comparative Effectiveness Research
Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL ...
Kerry A Rogers, Benyam Muluneh, Zaina P Qureshi, Jinghua He, Alex Bokun, Zhijie Ding, Marie-Helene Lafeuille, Priyanka Gogna, Bruno Emond, Michael Fradley   +9 more
doaj   +1 more source